SAB Biotherapeutics (SABS) Change in Accured Expenses (2020 - 2026)
SAB Biotherapeutics (SABS) posted Change in Accured Expenses of -$1.2 million for Q1 2026, down 202.63% on a QoQ basis from -$394856.0 in Q4 2025, and down 304.94% year-over-year from $583073.0 in Q1 2025.
SAB Biotherapeutics (SABS) Change in Accured Expenses (2020 - 2026) Analysis & Trends
SAB Biotherapeutics' Change in Accured Expenses history runs 7 years deep, the most recent figure standing at -$1.2 million for Q1 2026.
- Quarterly Change in Accured Expenses fell 304.94% year-over-year to -$1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$836515.0 (down 189.77% YoY) and the FY2025 annual result came in at $941524.0, up 176.48% from the prior year.
- Change in Accured Expenses was -$1.2 million for Q1 2026 at SAB Biotherapeutics, down from -$394856.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $1.9 million in Q3 2024 and bottomed at -$2.0 million in Q2 2022.
- A 5-year average of -$337477.3 and a median of -$394856.0 in 2025 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2025 — Change in Accured Expenses jumped 1661.16% — and 2026, when it tumbled 304.94%.
- SAB Biotherapeutics' Change in Accured Expenses stood at -$320231.0 in 2022, then jumped by 538.06% to $1.4 million in 2023, then plunged by 202.66% to -$1.4 million in 2024, then jumped by 72.58% to -$394856.0 in 2025, then plunged by 202.63% to -$1.2 million in 2026.
- Business Quant data shows SABS's Change in Accured Expenses at -$1.2 million in Q1 2026, -$394856.0 in Q4 2025, and -$287490.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -16.82 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -16.74 Mn |
| 10 | SAB Biotherapeutics | 170.64 Mn | 170.64 Mn | - | -1.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.19 Mn |
| Mar 31, 2026 | -1.19 Mn |
| Dec 31, 2025 | -394,856.00 |
| Dec 31, 2025 | -394,856.00 |
| Sep 30, 2025 | -287,490.00 |
| Sep 30, 2025 | -287,490.00 |
| Jun 30, 2025 | 1.04 Mn |
| Jun 30, 2025 | 1.04 Mn |
| Mar 31, 2025 | 583,073.00 |
| Mar 31, 2025 | 583,073.00 |
| Dec 31, 2024 | -1.44 Mn |
| Dec 31, 2024 | -1.44 Mn |
| Sep 30, 2024 | 1.86 Mn |
| Sep 30, 2024 | 1.86 Mn |
| Jun 30, 2024 | -66,668.00 |
| Jun 30, 2024 | -66,668.00 |
| Mar 31, 2024 | -1.58 Mn |
| Mar 31, 2024 | -1.58 Mn |
| Dec 31, 2023 | 1.40 Mn |
| Dec 31, 2023 | 1.40 Mn |